US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi Beauty, Skincare & Aesthetics ETF

27.77

-0.1591-0.57%

Volume:139

Turnover:4K

Market Cap:1.39M

PE:- -

High:27.95

Open:27.95

Low:27.77

Close:27.93

52wk High:29.89

52wk Low:24.32

Shares:50.00K

Float Shares:50.00K

Volume Ratio:0.69

T/O Rate:0.28%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Estee Lauder Cos. Cl a Stock Underperforms Wednesday When Compared to Competitors

AbbVie Wraps Key Early Trial on ABBV-722 Drug Interaction, Supporting Pipeline Confidence

AbbVie’s Bretisilocin Study Completion Signals Quiet Progress in Early-Stage Pipeline

From Walmart to Nestle, CEO Churn Sweeps Global Consumer Goods Makers

Major Drugmakers Turn to China for Licensing Deals

Kenvue Says Post-Hoc Phase III Analysis Links Earlier 5% Minoxidil Use to Higher Hair Regrowth in Men with Androgenetic Alopecia

AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart

AbbVie Starts Phase 2 Obesity Trial of Gubra-Discovered Amylin Analog ABBV-295

Abbvie: in Phase 1 Abbv-295 Study, All Dosing Regimens Resulted in Ls Mean Weight Loss up to About 10% over 3-Month Treatment Period

THOMSON REUTERS

Abbvie: 82.2% of All Abbv-295 Treated Participants Reported Mild Adverse Events as Highest Reported Ae Severity

THOMSON REUTERS

AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss up to About 10% over 3-Month Period

AbbVie Says Mid-Stage Study of Atopic Dermatitis Treatment Meets Primary Goal

MT Newswires Live

Abbvie Highlights Positive Results from the Phase 2 Apex Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at Eadv 2026

THOMSON REUTERS

AbbVie Presents Phase 2 APEX Part B Data for Zumilokibart in Moderate-to-Severe Atopic Dermatitis at EADV 2026

AbbVie Inc. Stock Outperforms Competitors Despite Losses on the Day

AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says

MT Newswires Live

Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium

MT Newswires Live

AbbVie Partners with Valkai to Deploy AI Across Clinical Development

Abbvie - to Deploy AI Via Valkai Partnership to Improve Clinical Research Efficiency

THOMSON REUTERS

Abbvie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/GLAM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GLAM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLAM\",,,,,undefined,":{"symbol":"GLAM","market":"US","secType":"STK","nameCN":"Corgi Beauty, Skincare & Aesthetics ETF","latestPrice":27.766,"timestamp":1790798400000,"preClose":27.9251,"halted":0,"volume":139,"delay":0,"changeRate":-0.005697383357624583,"floatShares":50000,"shares":50000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.1591,"latestTime":"10-01 05:03:51 EDT","open":27.95,"high":27.95,"low":27.766,"amount":3887,"amplitude":0.006589,"askPrice":44.14,"askSize":100,"bidPrice":11.17,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790861400000},"marketStatusCode":1,"adr":0,"exchange":"CBOE","adjPreClose":27.766,"nav":27.92,"aum":1396000,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.95,"preClose":27.766,"latestTime":"16:15 EDT","volume":8,"amount":222.128,"timestamp":1790799300221,"change":0.184,"changeRate":0.006627,"amplitude":0},"volumeRatio":0.6860811847269641,"impliedVol":0.5992,"impliedVolPercentile":0.7204},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLAM\",,,,,undefined,":{"symbol":"GLAM","floatShares":50000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6860811847269641,"shares":50000,"dividePrice":0,"high":27.95,"amplitude":0.006589,"preClose":27.9251,"low":27.766,"week52Low":24.3178,"pbRate":"--","week52High":29.89,"institutionHeld":0,"latestPrice":27.766,"eps":0,"divideRate":0,"volume":139,"delay":0,"ttmEps":0,"open":27.95,"prevYearClose":25.82,"prevWeekClose":28.1493,"prevMonthClose":27.766,"prevQuarterClose":27.766,"fiveDayClose":28.1821,"twentyDayClose":28.6876,"sixtyDayClose":28.3416},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GLAM\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GLAM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GLAM\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GLAM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672178765","title":"Estee Lauder Cos. Cl a Stock Underperforms Wednesday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2672178765","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672178765?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:55","pubTimestamp":1790801700,"startTime":"0","endTime":"0","summary":"DJ Estee Lauder Cos. Cl A Stock Underperforms Wednesday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Estee Lauder Cos. Cl A  slipped 1.70% to $92.77 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index  falling 0.25% to 7,651.54 and Dow Jones Industrial Average  falling 0.86% to 50,906.05.This was the stock's second consecutive day of losses.Estee Lauder Cos. Cl A closed 23.73% short of its 52-week high of $121.64, which the company reached on February 3rd.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Johnson & Johnson  fell 1.06% to $264.74, Procter & Gamble Co.  fell 2.05% to $145.28, and Coty Inc. Cl A  fell 2.97% to $2.61.Trading volume  eclipsed its 50-day average volume of 3.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 30, 2026.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2592432038.USD","XLP","IE00B1BXHZ80.USD","SG9999015341.SGD","LU1059921491.USD","LU1868837136.USD","BMED","LU1267930813.SGD","LU1585245621.USD","LU2347655156.SGD","UGE","VHT","LU1023059063.AUD","BK4183","FHLC","EL","LU1003077747.HKD","PJP","FSTA","JDOC","LU2505996509.AUD","JNJ","TRUH","GLAM","LU1196500208.SGD","BK4558","BK4533","LU0882574055.USD","LU0787776722.HKD","LU0661504455.SGD","IXJ","LU0057025933.USD","XLV","LU0690374961.EUR","LU2552382132.HKD","GDOC","LU2505996681.GBP","LU1066051811.HKD","IHE","COTY","IE000M9KFDE8.USD","TRUO","LU0124676726.USD","LU1496350502.SGD","PG","FTXH","RXL","BK4588","IYH","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672014786","title":"AbbVie Wraps Key Early Trial on ABBV-722 Drug Interaction, Supporting Pipeline Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2672014786","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672014786?lang=en_us&edition=fundamental","pubTime":"2026-10-01 00:30","pubTimestamp":1790785840,"startTime":"0","endTime":"0","summary":"Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie has completed a Phase 1 study called “A Phase 1 Study to Evaluate the Ef...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abbvie-wraps-key-early-trial-on-abbv-722-drug-interaction-supporting-pipeline-confidence?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abbvie-wraps-key-early-trial-on-abbv-722-drug-interaction-supporting-pipeline-confidence?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE000MB6IJN5.SGD","LU1934455863.HKD","LU2089284900.SGD","LU0256863902.USD","LU1496350171.SGD","LU1839511570.USD","LU0122379950.USD","BK4139","AGNG","MEDX","LU2468319806.SGD","LU0861579265.USD","BK4534","LU0417517546.SGD","LU1093756168.USD","LU0289739699.SGD","IXJ","ABBV","LU0795875169.SGD","LU1061106388.HKD","GLAM","JDOC","PPH","LU0738911758.USD","IE0002270589.USD","XLV","TRUH","PJP","LU0029864427.USD","LU0820561818.USD","LU1430594728.SGD","BK4585","LU1934455194.USD","IYH","IE00BSNM7G36.USD","BK4533","LU1720051108.HKD","LU0965509010.AUD","FHLC","RXL","LU1929549753.HKD","SG9999015978.USD","SG9999001440.SGD","LU0689472784.USD","LU1093756325.SGD","LU0128525929.USD","FTXH","VHT","LU0310800379.SGD","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672860737","title":"AbbVie’s Bretisilocin Study Completion Signals Quiet Progress in Early-Stage Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2672860737","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672860737?lang=en_us&edition=fundamental","pubTime":"2026-10-01 00:30","pubTimestamp":1790785833,"startTime":"0","endTime":"0","summary":"Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie has completed a Phase 1 study called “An Open-Label Study to Evaluate th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abbvies-bretisilocin-study-completion-signals-quiet-progress-in-early-stage-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abbvies-bretisilocin-study-completion-signals-quiet-progress-in-early-stage-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1244550494.USD","AGNG","FHLC","LU0553294199.USD","LU0289739699.SGD","VHT","LU1244550221.USD","MEDX","IXJ","JDOC","LU0545039389.USD","LU1162221912.USD","RXL","LU2089283258.USD","BK4097","BK4534","LU1057294990.SGD","LU1989772840.SGD","ABBV","LU0511384066.AUD","LU0114720955.EUR","LU2089284900.SGD","LU0943347566.SGD","SG9999003800.SGD","IE0009355771.USD","IE00B42XCP33.USD","LU2347655073.USD","LU0708994859.HKD","LU2237443382.USD","GLAM","IE00BSNM7G36.USD","LU1061106388.HKD","LU1934455863.HKD","LU0823416689.USD","LU2237443895.HKD","PRGS","LU2129689431.USD","LU0256863902.USD","TRUH","LU1718418525.SGD","LU2237443465.HKD","PPH","IE00BGHQF631.EUR","IE00BJT1NW94.SGD","LU0170899867.USD","LU2129689605.HKD","PJP","FTXH","IYH","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671075912","title":"From Walmart to Nestle, CEO Churn Sweeps Global Consumer Goods Makers","url":"https://stock-news.laohu8.com/highlight/detail?id=2671075912","media":"Reuters","labels":["executive","event","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671075912?lang=en_us&edition=fundamental","pubTime":"2026-09-30 21:18","pubTimestamp":1790774302,"startTime":"0","endTime":"0","summary":"FACTBOX-From Walmart to Nestle, CEO churn sweeps global consumer goods makersSept 30 (Reuters)-Toymaker MattelMAT.Oand Cheerios maker General MillsGIS.Non Wednesday named new chief executive officers,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL6N45M0TB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1046421449.USD","XLP","03165","WMT","SG9999014559.SGD","RSPS","LULU","SJM","HSY","WMTI","RTH","BREW","CAG","FTXG","MAT","UGE","STYL","ULVR.UK","KHC","KR","WEN","SPFE0main","DPZ","LU2471134523.USD","FBIN","SKO00main","LULG","SWK","TRUO","FSTA","TSN","DG","GLAM","BBY","BK4146","GIS","BK4567","DGE.UK","COTY","KSS","LU0550127509.SGD","NICO","NKE","MO","TGT","HRL","KVUE","PBJ","KO","PG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671051201","title":"Major Drugmakers Turn to China for Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2671051201","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671051201?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:17","pubTimestamp":1790770671,"startTime":"0","endTime":"0","summary":"FACTBOX-Major drugmakers turn to China for licensing dealsSept 30 (Reuters)-Novo NordiskNOVOb.COsaid on Tuesday it will pay up to$2.6 billionto Jiangsu Hengrui Pharmaceuticals600276.SSfor the rights t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL4N45M0T3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RSHO","THNR","LLII","ELIS","IXJ","ILDR","FHLC","688331","PFE","ELIL","SMMT","GLAM","LLY","PAWZ","CANC","CURE","FTXH","TMED","MEDI","01530","VHT","OZEM","03692","AGNG","HRTS","ABBV","KURE","PPH","00013","RXL","09926","WDNA","TRUH","LLYX","MRK","BMED","GSK.UK","PJP","IHE","MEDX","JDOC","GDOC","600276","01801","LLYZ","MHIP","BNTX","CGNX","IYH","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671205985","title":"Kenvue Says Post-Hoc Phase III Analysis Links Earlier 5% Minoxidil Use to Higher Hair Regrowth in Men with Androgenetic Alopecia","url":"https://stock-news.laohu8.com/highlight/detail?id=2671205985","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671205985?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:45","pubTimestamp":1790765154,"startTime":"0","endTime":"0","summary":"Kenvue says post-hoc Phase III analysis links earlier 5% minoxidil use to higher hair regrowth in men with androgenetic alopeciaKenvue outlined new clinical and preclinical findings slated for present","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL8jHf4f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNV92.GBP","GLAM","PJP","IXJ","FHLC","IE00B2B36J28.USD","TRUH","MEDX","LU0345770308.USD","LU2471134952.CNY","LU1267930573.SGD","LU1196500208.SGD","LU1894683348.USD","SG9999001176.SGD","JNJ","LU2487616109.SGD","JDOC","RXL","BK4592","LU1032955483.USD","LU0787776722.HKD","VHT","IE000WAW04H5.SGD","IE00B4R5TH58.HKD","BMED","BK4581","LU1778281490.HKD","LU0912757837.SGD","LU2236285917.USD","FTXH","LU0289739699.SGD","LU0738911758.USD","LU2089984988.USD","LU0661504455.SGD","KVUE","IYH","IE0002141913.USD","GDOC","SG9999001440.SGD","LU1244550221.USD","XLV","SG9999001176.USD","LU0689626769.HKD","RSPS","LU0792757196.USD","LU0128525929.USD","IHE","LU2471134796.USD","LU1003077747.HKD","LU1145028129.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671089252","title":"AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart","url":"https://stock-news.laohu8.com/highlight/detail?id=2671089252","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671089252?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:55","pubTimestamp":1790762110,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study, evaluating zumilokibart, in adult...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbvie-reports-positive-results-from-phase-2-apex-part-b-study-of-zumilokibart-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbvie-reports-positive-results-from-phase-2-apex-part-b-study-of-zumilokibart-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0000B7K699.USD","IE00BLSP4452.SGD","IE00B19Z3581.USD","IXJ","BK4533","LU0234572021.USD","FHLC","GLAM","FTXH","LU1670628061.USD","IE000F7OJYX1.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE000SO60NU8.SGD","LU2089284900.SGD","VHT","LU0820561909.HKD","LU1430594728.SGD","IE0002141913.USD","LU1057294990.SGD","BK4566","AGNG","ABBV","BK4550","PPH","LU1037948541.HKD","RXL","LU1732800096.USD","LU2023251221.USD","LU2347655156.SGD","TRUH","LU1720051108.HKD","IE00B3PB1722.GBP","LU1989772923.USD","LU1934455277.USD","PJP","MEDX","JDOC","LU0256863811.USD","LU0058720904.USD","LU0395794307.EUR","LU0472753341.HKD","LU0114720955.EUR","LU2347655073.USD","LU0057025933.USD","IYH","LU0203345920.USD","XLV","LU0553294199.USD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671208859","title":"AbbVie Starts Phase 2 Obesity Trial of Gubra-Discovered Amylin Analog ABBV-295","url":"https://stock-news.laohu8.com/highlight/detail?id=2671208859","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671208859?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:51","pubTimestamp":1790761876,"startTime":"0","endTime":"0","summary":"AbbVie starts Phase 2 obesity trial of Gubra-discovered amylin analog ABBV-295Gubra flagged AbbVie’s detailed Phase 1 results for obesity candidate ABBV-295, presented at EASD 2026 in Milan.Data showe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL9BGxfn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739343.SGD","LU1037948897.HKD","PJP","VHT","IE00BJT1NW94.SGD","LU1983299246.USD","SG9999015952.SGD","IE00BVYPNV92.GBP","LU1037948541.HKD","LU1989772923.USD","LU2112291526.USD","IE00B4R5TH58.HKD","LU1934455863.HKD","GLAM","LU0310800379.SGD","LU2237443978.SGD","IYH","AGNG","LU1267930490.SGD","LU0738911758.USD","LU0820561909.HKD","FHLC","LU0859254822.USD","LU0912757837.SGD","LU0417517546.SGD","MEDX","LU1718418525.SGD","LU0708994859.HKD","PPH","LU0058720904.USD","LU1093756168.USD","LU2357305700.SGD","IXJ","FTXH","LU0661504455.SGD","XLV","LU1923622614.USD","LU2125909247.SGD","LU0310799852.SGD","LU0069063385.USD","LU0985320562.USD","TRUH","LU1430594728.SGD","ABBV","LU0170899867.USD","JDOC","LU2237443622.USD","LU0289961442.SGD","RXL","LU0456855351.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671270785","title":"Abbvie: in Phase 1 Abbv-295 Study, All Dosing Regimens Resulted in Ls Mean Weight Loss up to About 10% over 3-Month Treatment Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2671270785","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671270785?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:45","pubTimestamp":1790761500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nP8N3WW07N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1037948897.HKD","LU1093756168.USD","BK4534","LU0198837287.USD","SG9999015952.SGD","IE00BJJMRZ35.SGD","LU0124676726.USD","LU1934455863.HKD","LU0417517546.SGD","LU1267930490.SGD","GLAM","LU0868494617.USD","VHT","LU0289739343.SGD","LU0820561909.HKD","IE000BZT7R73.USD","LU1934455194.USD","LU1983299246.USD","ABBV","BK4559","IE00BGHQF631.EUR","IYH","LU0203345920.USD","LU0395794307.EUR","IE0004445239.USD","LU0234570918.USD","RXL","TRUH","JDOC","MEDX","IE0002141913.USD","LU0058720904.USD","LU0203347892.USD","LU0949170772.SGD","LU2129689431.USD","XLV","LU1839511570.USD","LU1244550494.USD","LU2087621335.USD","AGNG","PPH","IE00BBT3K403.USD","IE00BJT1NW94.SGD","PJP","LU0320765646.SGD","IXJ","LU1236620750.USD","FTXH","FHLC","LU0057025933.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671270207","title":"Abbvie: 82.2% of All Abbv-295 Treated Participants Reported Mild Adverse Events as Highest Reported Ae Severity","url":"https://stock-news.laohu8.com/highlight/detail?id=2671270207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671270207?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:45","pubTimestamp":1790761500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nP8N3WW07N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999011175.SGD","LU2087621335.USD","LU2089283258.USD","LU0395794307.EUR","ABBV","GLAM","LU0158827948.USD","IE00BSNM7G36.USD","IXJ","LU1989772840.SGD","LU1720051017.SGD","LU2347655156.SGD","IE000BZT7R73.USD","TRUH","LU1732800096.USD","LU1430594728.SGD","LU1037948897.HKD","LU2357627491.SGD","LU1244550577.SGD","VHT","LU0943347566.SGD","LU1989771016.USD","LU0057025933.USD","XLV","BK4534","MEDX","RXL","IE0002141913.USD","BK4533","LU0289739699.SGD","IE000SO60NU8.SGD","FHLC","IE00BLSP4239.USD","IE0009355771.USD","LU0689626769.HKD","LU1267930573.SGD","BK4139","IYH","LU2237443549.SGD","PJP","FTXH","LU0795875169.SGD","AGNG","SG9999015978.USD","LU0545039389.USD","LU0128525929.USD","LU0985320562.USD","PPH","JDOC","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671208209","title":"AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss up to About 10% over 3-Month Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2671208209","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671208209?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:45","pubTimestamp":1790761500,"startTime":"0","endTime":"0","summary":"BRIEF-AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss Up To About 10% Over 3-Month PeriodSept 30 -AbbVie Inc.ABBV.N:ABBVIE: IN PHASE 1 ABBV-295 STUDY, ALL DOSING REGIMENS RESULTED IN LS MEAN WEIGHT LOSS UP TO ABOUT 10% OVER 3-MONTH TREATMENT PERIODABBVIE: 82.2% OF ALL ABBV-295 TREATED PARTICIPANTS REPORTED MILD ADVERSE EVENTS AS HIGHEST REPORTED AE SEVERITYFurther company coverage:ABBV.N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nP8N3WW07N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU0114720955.EUR","LU0098860793.USD","LU1093756168.USD","LU1670627923.USD","LU0310799852.SGD","SG9999015952.SGD","IE0004445239.USD","LU0057025933.USD","LU0823416689.USD","LU1037948897.HKD","LU0965508806.USD","LU0158827948.USD","LU2357305700.SGD","RXL","LU1732800096.USD","LU1839511570.USD","AGNG","LU1291159041.SGD","IYH","IE00BN8TJ469.HKD","FHLC","MEDX","FTXH","LU0310800379.SGD","GLAM","PPH","LU2087621335.USD","LU1496350502.SGD","LU1934455277.USD","TRUH","JDOC","LU0820561909.HKD","LU1430594728.SGD","LU2089984988.USD","SG9999015978.USD","LU1548497426.USD","PJP","LU0256863902.USD","LU1983299246.USD","IXJ","LU0320765646.SGD","LU0472753341.HKD","LU2112291526.USD","BK4566","LU0432979614.USD","LU0689472784.USD","ABBV","XLV","VHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671271707","title":"AbbVie Says Mid-Stage Study of Atopic Dermatitis Treatment Meets Primary Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2671271707","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671271707?lang=en_us&edition=fundamental","pubTime":"2026-09-30 16:14","pubTimestamp":1790756080,"startTime":"0","endTime":"0","summary":"AbbVie's  phase 2 dose-finding study of zumilokibart in adults with moderate-to-severe atopic dermatitis met its primary endpoint, with all three dose regimens achieving \"significantly\" higher response rates at week 16, compared with placebo, the company said Wednesday.The mid-dose regimen has been selected for phase 3 development.The findings support further evaluation of the drug's efficacy, safety and extended dosing intervals as a potential long-term treatment option, AbbVie said.Atopic dermatitis is a condition that causes dry, itchy and inflamed skin.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0069063385.USD","LU2357305700.SGD","LU0708994859.HKD","IE00BVYPNW00.USD","IXJ","IE00BSNM7G36.USD","LU0456855351.SGD","FHLC","LU0965509101.SGD","GLAM","IE00BFTCPJ56.SGD","FTXH","LU1670628061.USD","LU1983299246.USD","LU0943347566.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE000SO60NU8.SGD","VHT","LU0820561909.HKD","AGNG","ABBV","BK4550","PPH","BK4534","LU0965509010.AUD","RXL","IE00BJT1NW94.SGD","LU1732800096.USD","LU2023251221.USD","TRUH","LU1585245621.USD","LU1003077747.HKD","PJP","LU1934455863.HKD","LU1496350171.SGD","BK4588","JDOC","MEDX","LU0256863811.USD","LU0211328371.USD","LU1720051017.SGD","SG9999015945.SGD","LU0289739343.SGD","IYH","IE00BDGV0183.EUR","IE000WAW04H5.SGD","XLV","LU0511384066.AUD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671220206","title":"Abbvie Highlights Positive Results from the Phase 2 Apex Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at Eadv 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2671220206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671220206?lang=en_us&edition=fundamental","pubTime":"2026-09-30 13:30","pubTimestamp":1790746200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUAFW3VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BFTCPJ56.SGD","LU1929549753.HKD","LU0170899867.USD","AGNG","LU0256863902.USD","LU1670627923.USD","IE0009355771.USD","LU2347655156.SGD","LU1496350502.SGD","LU1548497426.USD","FHLC","LU2125909593.SGD","LU0820561818.USD","BK4550","LU1551013425.SGD","FTXH","XLV","IE00BN8TJ469.HKD","LU1496350171.SGD","TRUH","LU1162221912.USD","LU0738911758.USD","SG9999015986.USD","ABBV","BK4581","LU0942090050.USD","IE0002141913.USD","LU2089284900.SGD","IE00BSNM7G36.USD","PJP","JDOC","IE00B4R5TH58.HKD","LU1061106388.HKD","LU1720051017.SGD","LU2125909247.SGD","MEDX","RXL","LU0708994859.HKD","IXJ","LU1003077747.HKD","LU1037948541.HKD","PPH","LU0472753341.HKD","IYH","VHT","LU0511384066.AUD","LU0949170772.SGD","LU1718418525.SGD","GLAM","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671220398","title":"AbbVie Presents Phase 2 APEX Part B Data for Zumilokibart in Moderate-to-Severe Atopic Dermatitis at EADV 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2671220398","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671220398?lang=en_us&edition=fundamental","pubTime":"2026-09-30 13:01","pubTimestamp":1790744482,"startTime":"0","endTime":"0","summary":"AbbVie presents Phase 2 APEX Part B data for zumilokibart in moderate-to-severe atopic dermatitis at EADV 2026AbbVie flagged new dermatology trial and real-world results slated for presentation at the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL524zqn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","LU0320765646.SGD","LU1244550494.USD","PPH","LU2089284900.SGD","IE00B19Z3581.USD","LU0795875086.SGD","LU2237443895.HKD","LU1585245621.USD","LU1057294990.SGD","LU0417517546.SGD","LU1718418525.SGD","LU1934455277.USD","PJP","XLV","LU2347655073.USD","LU1934455863.HKD","LU2468319806.SGD","FHLC","GLAM","LU0289739699.SGD","LU2237443382.USD","FTXH","LU2133065610.SGD","LU0738911758.USD","LU1074936037.SGD","LU2089283258.USD","IE00B2B36J28.USD","LU1496350171.SGD","RXL","MEDX","IYH","ABBV","IE000SO60NU8.SGD","LU0949170772.SGD","LU1923622614.USD","LU2129689431.USD","SG9999015952.SGD","VHT","LU1291159041.SGD","LU2357627491.SGD","LU0689472784.USD","LU0472753341.HKD","AGNG","JDOC","TRUH","IE000F7OJYX1.SGD","LU0661504455.SGD","IXJ","LU0098860793.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671247344","title":"AbbVie Inc. Stock Outperforms Competitors Despite Losses on the Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2671247344","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671247344?lang=en_us&edition=fundamental","pubTime":"2026-09-30 04:31","pubTimestamp":1790713860,"startTime":"0","endTime":"0","summary":"DJ AbbVie Inc. Stock Outperforms Competitors Despite Losses On The DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of AbbVie Inc.  slipped 1.12% to $263.29 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index  falling 0.17% to 7,670.84 and Dow Jones Industrial Average  falling 0.26% to 51,349.92.AbbVie Inc. closed 2.26% short of its 52-week high of $269.39, which the company reached on September 23rd.The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Johnson & Johnson  fell 1.61% to $267.57, Pfizer Inc.  remained unchanged, and Amgen Inc.  rose 1.32% to $423.64.Trading volume  remained 775,865 below its 50-day average volume of 4.7 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 29, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU0545039389.USD","LU0256863902.USD","LU2089283258.USD","LU2347655073.USD","LU0211327993.USD","LU1236620834.HKD","LU2023251221.USD","LU0203345920.USD","LU0726765562.USD","IE00BN8TJ469.HKD","LU0708994859.HKD","LU0122379950.USD","LU0820561818.USD","LU0029864427.USD","LU2125909593.SGD","IE00BVYPNV92.GBP","VHT","LU1496350502.SGD","IE00BGHQF631.EUR","IYH","LU1670628061.USD","LU2129689431.USD","SG9999001440.SGD","BK4585","LU0738911758.USD","BK4139","LU2087621335.USD","LU1244550494.USD","LU1934455863.HKD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0256863811.USD","BK4581","LU1548497426.USD","FHLC","LU2433249047.HKD","LU0289739343.SGD","LU1720051017.SGD","LU1037948541.HKD","IE0002270589.USD","LU0912757837.SGD","LU1291159041.SGD","LU2129689605.HKD","LU0795875086.SGD","LU0823416689.USD","IXJ","LU1162221912.USD","ABBV","PPH","LU0417517546.SGD","LU0689626769.HKD","LU1732799900.SGD","MEDX","LU0310800379.SGD","LU0689472784.USD","PJP","LU0949170772.SGD","IE00B19Z3B42.SGD","IE000BZT7R73.USD","LU1093756325.SGD","BK4533","LU1551013342.USD","LU0128525929.USD","LU0289739699.SGD","LU1983299246.USD","RXL","IE0004445239.USD","LU1496350171.SGD","LU2237443978.SGD","LU1430594728.SGD","LU1732800096.USD","IE00B42XCP33.USD","IE000MB6IJN5.SGD","LU1061106388.HKD","LU1551013425.SGD","LU2129689514.USD","LU2357627491.SGD","IE00BFTCPJ56.SGD","LU0943347566.SGD","LU0234570918.USD","LU1929549753.HKD","LU0456855351.SGD","GLAM","LU0965509283.SGD","BK4566","BK4550","LU0395794307.EUR","LU1720051108.HKD","LU0472753341.HKD","LU1934455277.USD","LU1839511570.USD","LU1989772840.SGD","LU0511384066.AUD","JDOC","LU1934455194.USD","BK4534","IE000F7OJYX1.SGD","LU2112291526.USD","BK4588","LU0057025933.USD","IE000SO60NU8.SGD","LU1074936037.SGD","LU0965508806.USD","LU0069063385.USD","LU0124676726.USD","LU0310799852.SGD","LU0158827948.USD","LU0795875169.SGD","LU0211328371.USD","LU2468319806.SGD","LU0861579265.USD","IE00BDGV0183.EUR","LU0882574055.USD","LU0098860793.USD","LU0289961442.SGD","LU0965509101.SGD","IE0000B7K699.USD","LU0661504455.SGD","LU0868494708.USD","LU2089984988.USD","BK4559","IE00B19Z3581.USD","LU2237443622.USD","LU1093756168.USD","LU1267930573.SGD","LU2133065610.SGD","LU0114720955.EUR","LU0058720904.USD","LU1037948897.HKD","LU0320765646.SGD","AGNG","LU0942090050.USD","SG9999011175.SGD","SG9999015986.USD","IE000WAW04H5.SGD","IE00BLSP4239.USD","LU0868494617.USD","LU0234572021.USD","LU0965509010.AUD","LU2237443465.HKD","LU0203347892.USD","LU1003077747.HKD","LU1057294990.SGD","LU2237443549.SGD","LU1989771016.USD","IE00BVYPNW00.USD","LU1236620750.USD","SG9999015978.USD","LU1989772923.USD","LU0820561909.HKD","LU0553294199.USD","IE00BSNM7G36.USD","LU2347655156.SGD","IE0002141913.USD","LU1670627923.USD","IE00BJJMRZ35.SGD","LU0170899867.USD","LU1718418525.SGD","LU0198837287.USD","SG9999015945.SGD","IE00B3PB1722.GBP","LU2237443382.USD","TRUH","LU1923622614.USD","XLV","LU1244550577.SGD","LU2089284900.SGD","LU2125909247.SGD","LU2237443895.HKD","LU0859254822.USD","LU2357305700.SGD","LU1585245621.USD","LU0985320562.USD","SG9999003800.SGD","LU1267930490.SGD","LU0432979614.USD","SG9999015952.SGD","LU1244550221.USD","IE00BBT3K403.USD","LU1023059063.AUD","FTXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671524591","title":"AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2671524591","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671524591?lang=en_us&edition=fundamental","pubTime":"2026-09-29 23:49","pubTimestamp":1790696980,"startTime":"0","endTime":"0","summary":"AbbVie  shows pipeline-driven upside beyond the core immunology franchise, with outlook for its oncology and neuroscience segments likely becoming clearer over the next one to two years, BofA said in a Tuesday research note.In oncology, the company's antibody-drug conjugate portfolio, particularly temab-A and ABBV-969, have shown encouraging early efficacy and can exceed expectations if later-stage studies are successful, according to the note.Meanwhile, in neuroscience, growth has been supported by products related to Parkinson's disease, migraine, and botox therapeutic, BofA said, adding that the loss of exclusivity for Vraylar limits longer-term category growth.BofA reiterated its buy rating with a $289 price target.Price: 263.09, Change: -3.19, Percent Change: -1.20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1989771016.USD","BK4550","GLAM","FHLC","IYH","LU0198837287.USD","LU0553294199.USD","LU1496350171.SGD","FTXH","BK4533","LU1291159041.SGD","IE000MB6IJN5.SGD","LU2125909593.SGD","LU0211327993.USD","LU1074936037.SGD","LU0795875086.SGD","BK4581","LU1244550577.SGD","LU2023251221.USD","MEDX","IE00B19Z3581.USD","XLV","IE00BFTCPJ56.SGD","ABBV","LU0661504455.SGD","LU1236620834.HKD","LU2347655073.USD","JDOC","LU0417517546.SGD","IXJ","TRUH","LU2125909247.SGD","LU0289739343.SGD","LU0310800379.SGD","PPH","RXL","PJP","LU1929549753.HKD","LU1551013425.SGD","LU0820561909.HKD","VHT","LU2237443978.SGD","AGNG","IE00BJT1NW94.SGD","LU0029864427.USD","IE00BDGV0183.EUR","LU2112291526.USD","IE0002270589.USD","LU1551013342.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671142248","title":"Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium","url":"https://stock-news.laohu8.com/highlight/detail?id=2671142248","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671142248?lang=en_us&edition=fundamental","pubTime":"2026-09-29 22:31","pubTimestamp":1790692316,"startTime":"0","endTime":"0","summary":"Ginkgo Bioworks'  Datapoints and Apheris said Tuesday that AbbVie , argenx , Lundbeck, and Takeda  will join them as founding members of the Antibody Developability Consortium.The consortium is designed to help pharmaceutical and biotech companies predict manufacturability and developability risks earlier by building the field's largest standardized antibody developability dataset, according to a statement.The companies said that each founding member will contribute proprietary antibody sequences, with Ginkgo Datapoints filling any remaining capacity from publicly available sources to reach a total of 10,000 antibodies.The consortium is targeting an initial dataset by early 2027, they added.Price: 11.01, Change: +0.55, Percent Change: +5.26","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TBXU","LU0661504455.SGD","PPH","VHT","LU1061106388.HKD","LU0868494708.USD","BK4007","LU1732800096.USD","IE00BJT1NW94.SGD","IE0002141913.USD","LU0128525929.USD","GLAM","ARGX","LU1670628061.USD","FTXH","MEDX","IE00BSNM7G36.USD","LU0689472784.USD","IE00B3PB1722.GBP","LU0889565916.HKD","IE00BGHQF631.EUR","BK4534","LU1670627923.USD","LU0320765646.SGD","FHLC","ABBV","PJP","LU2357627491.SGD","IXJ","DNA","XLV","IE000BZT7R73.USD","IE00B42XCP33.USD","SG9999015945.SGD","TRUH","IE0002270589.USD","BK4533","JDOC","IYH","IE0004445239.USD","AGNG","FMED","LU1585245621.USD","TAK","DNA.AU","LU0211327993.USD","LU2023251221.USD","RXL","IBB","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671212100","title":"AbbVie Partners with Valkai to Deploy AI Across Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2671212100","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671212100?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:03","pubTimestamp":1790687000,"startTime":"0","endTime":"0","summary":"AbbVie partners with Valkai to deploy AI across clinical developmentAbbVie entered a partnership with Valkai to deploy AI tools across targeted areas of clinical development.Collaboration aims to impr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL8NKYd1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","LU0211327993.USD","LU1934455863.HKD","LU2125909593.SGD","FHLC","FTXH","IE00B19Z3581.USD","LU0689626769.HKD","IXJ","XLV","IE00B42XCP33.USD","LU0122379950.USD","IYH","BK4585","LU0912757837.SGD","LU1496350502.SGD","LU1037948897.HKD","RXL","IE000WAW04H5.SGD","LU2089284900.SGD","BK4581","LU0289739343.SGD","IE00BLSP4452.SGD","LU1670628061.USD","VHT","GLAM","LU0310799852.SGD","LU0820561909.HKD","LU0417517546.SGD","LU1037948541.HKD","LU1923622614.USD","LU1236620750.USD","LU2237443622.USD","PJP","LU1670627923.USD","ABBV","LU1244550577.SGD","AGNG","LU0472753341.HKD","LU0310800379.SGD","LU0859254822.USD","IE00B19Z3B42.SGD","LU1839511570.USD","JDOC","IE00BBT3K403.USD","IE00B4R5TH58.HKD","LU0211328371.USD","TRUH","LU0057025933.USD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671212631","title":"Abbvie - to Deploy AI Via Valkai Partnership to Improve Clinical Research Efficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2671212631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671212631?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:00","pubTimestamp":1790686814,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L0VO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0211328371.USD","LU1023059063.AUD","LU0949170772.SGD","IE000SO60NU8.SGD","MEDX","LU2089283258.USD","LU0069063385.USD","XLV","LU0058720904.USD","LU1718418525.SGD","LU0859254822.USD","LU1037948897.HKD","LU0098860793.USD","TRUH","LU1670628061.USD","LU1934455194.USD","IE0000B7K699.USD","LU1061106388.HKD","IE00BBT3K403.USD","SG9999015986.USD","LU2237443382.USD","VHT","JDOC","FTXH","IE00BN8TJ469.HKD","IYH","AGNG","FHLC","LU0820561818.USD","LU2347655156.SGD","PJP","LU1057294990.SGD","RXL","LU2125909247.SGD","LU0726765562.USD","LU2357305700.SGD","LU1291159041.SGD","IXJ","SG9999015952.SGD","IE00B42XCP33.USD","LU1732800096.USD","IE00BSNM7G36.USD","LU0122379950.USD","PPH","LU0868494708.USD","LU0511384066.AUD","LU1670627923.USD","ABBV","IE0004445239.USD","GLAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671212614","title":"Abbvie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2671212614","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671212614?lang=en_us&edition=fundamental","pubTime":"2026-09-29 21:00","pubTimestamp":1790686814,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nFWN45L0VO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1093756168.USD","LU1074936037.SGD","IE00BJJMRZ35.SGD","LU2023251221.USD","IE00BSNM7G36.USD","SG9999011175.SGD","LU2237443465.HKD","LU0868494708.USD","LU1267930490.SGD","GLAM","VHT","LU0289961442.SGD","LU1983299246.USD","ABBV","LU0256863811.USD","BK4559","BK4581","IYH","LU0553294199.USD","LU1267930573.SGD","LU1718418525.SGD","LU0234570918.USD","LU1291159041.SGD","LU1929549753.HKD","RXL","TRUH","JDOC","IE0009355771.USD","MEDX","LU0029864427.USD","LU0310799852.SGD","LU0472753341.HKD","XLV","LU2112291526.USD","IE00B3PB1722.GBP","LU0965508806.USD","LU1839511570.USD","BK4588","AGNG","LU1720051017.SGD","IE00BBT3K403.USD","PPH","PJP","IXJ","FTXH","FHLC","LU0795875086.SGD","LU2237443895.HKD","LU2468319806.SGD","LU1670628061.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}